Streetbeat News

SEOVF

Sernova Corp.

http://www.sernova.com/

CEO

Philip Toleikis

Industry

Research and Development in Biotechnology

Open

0.12

Mkt cap

39M

Volume

66K

High

0.12

P/E Ratio

-1.71

52-wk high

0.45

Low

0.12

Div yield

N/A

52-wk low

0.12

Sernova Biotherapeutics has appointed Dr. Pericles Calias as Chief Development Officer and Head of R&D. Dr. Calias is expected to bring operational depth and cell therapy expertise to the company.

Portfolio Pulse from

March 10, 2025 | 12:15 pm

Sernova Biotherapeutics has secured a CAD$1 million convertible debt financing from Dr. Steven Sangha, a shareholder and board member. The funds will be used for working capital.

Portfolio Pulse from

March 05, 2025 | 1:15 pm

Sernova Biotherapeutics has received FDA clearance for its IND application to evaluate its Cell Pouch with autograft thyroid cells in patients with hypothyroidism. This development could significantly impact the treatment of hypothyroidism, a condition affecting millions globally.

Portfolio Pulse from

March 03, 2025 | 2:15 pm

Sernova Biotherapeutics has submitted an IND application to the FDA for its Cell Pouch bio-hybrid organ with autograft thyroid cells, targeting patients with hypothyroidism. This marks a significant step in their regenerative medicine efforts.

Portfolio Pulse from

February 03, 2025 | 1:15 pm

Sernova Corp. has rescheduled its annual general and special meeting of shareholders to January 10, 2025, due to a postal strike in Canada. The meeting was originally set for January 7, 2025.

Portfolio Pulse from

December 20, 2024 | 1:15 pm

Raymond James analyst Rahul Sarugaser initiates coverage on Sernova (OTC:SEOVF) with a Market Perform rating and a price target of $1.5.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 5:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.